Malaysia’s pharmaceutical market is poised for steady growth in the coming years, driven by improved market access under a new Malaysia–US trade agreement and sustained government healthcare spending, according to a report by BMI, a Fitch Solutions company.
BMI said the recently signed Malaysia–US Agreement on Reciprocal Trade (ART), inked on October 28, 2025 during the 47th ASEAN Summit, will streamline drug approvals and enhance access to US-made medicines by reducing regulatory barriers.
Under the agreement, Malaysia will recognise US Food and Drug Administration (FDA) certificates and prior authorisations for medicines, effectively allowing automatic recognition of FDA-approved products unless serious safety issues arise. This, BMI noted, will accelerate product launches and reduce market entry barriers for US pharmaceutical exporters.
However, the think tank cautioned that the move could intensify competition for local manufacturers even as it improves access to high-quality medicines. The agreement is expected to take effect within 60 days of legal ratification.
BMI forecasts Malaysia’s pharmaceutical market to expand from MYR15.7 billion (USD3.4 billion) in 2025 to MYR21.4 billion (USD4.5 billion) by 2029, reflecting a compound annual growth rate (CAGR) of 6.4% in local currency terms.
Health Budget to Support Demand
Malaysia’s 2026 federal budget, tabled on October 10, 2025, reinforced the government’s commitment to healthcare, with the Ministry of Health (MoH) receiving a record allocation of MYR46.5 billion (USD11 billion) — up MYR1.2 billion from the previous year.
BMI said the emphasis on medicine supply security and cost containment will drive pharmaceutical procurement and open opportunities for generic and biosimilar drugs. The budget priorities align with the 13th Malaysia Plan and the Health White Paper, which aim to enhance healthcare accessibility and affordability.
Price Controls to Weigh on Margins
Despite the positive outlook, BMI warned that ongoing medicine price regulation will continue to pressure pharmaceutical margins.
Since the Ministry of Health’s strategic price regulation initiative launched in August 2024, authorities have pursued a two-phase reform — first to streamline drug registration through the National Pharmaceutical Regulatory Agency (NPRA), and second to strengthen government procurement and price negotiations.
While these measures aim to secure fairer prices and greater access to medicines, BMI cautioned that profit margins may narrow and operational pressures could rise for drugmakers due to increased scrutiny and tighter cost controls.
“The success of the initiative will depend on consistent enforcement and industry cooperation,” BMI noted, adding that the government’s focus on affordability could reshape the sector’s competitive landscape.
BMI concluded that Malaysia’s pharmaceutical industry stands at a “turning point” — with regulatory liberalisation and fiscal prioritisation fuelling growth, even as price pressures and global competition test the sector’s resilience.
